ºÚÁÏÍø

ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 2091

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

Trendy guidelines for the treatment of hepatocelular carcinoma

16th International Conference on Gastroenterology and Digestive Disorders

Gustavo Aguilar M.D

Hospital General San Juan de Dios, Guatemala

Posters & Accepted Abstracts: J Gastrointest Dig Syst

DOI:

Abstract
During the last years, Hepatocellular Carcinoma has become a public health issue in many countries. It is strongly related to cirrhosis that´s why surveillance each six months is recommended, than it allows diagnosis at an early stage, when effective therapies are possible. The best candidates for resection are patients with a solitary tumor and preserved liver function on the other hand liver transplantation is indicated in patients who are not good candidates for surgical resection, but are still meet in Milan or UCSF criteria for that matter. Image-guided ablation is the most frequently used therapeutic strategy, but its efficacy is limited by the size of the tumor and its localization. Trans arterial Chemoembolization has a survival benefit in patients with multifocal disease without vascular invasion or extrahepatic spread. Finally, sorafenib, lenvatinib, and regorafenib are the standard treatments in advanced hepatocellular carcinoma. This lecture gives a brief summary of the scientific evidence that supports the current recommendations for clinical practice.
Biography

E-mail: gusaguilarruiz@gmail.com

 

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top